This study is testing a program called CoMPASS (Contingency Management with stepped care to PrEP Adherence and Support Services) to help prevent HIV. CoMPASS combines support for taking PrEP (pre-exposure prophylaxis, a medicine to prevent HIV) with services for opioid use disorder. You might be able to join if you are 18 or older, have injected drugs in your lifetime, and meet criteria for PrEP. The study wants to see if CoMPASS helps people consistently take PrEP for 24 weeks. The study is currently recruiting about 526 participants, but its exact status is unclear.

Study design

This is a multi-site randomized clinical trial, meaning participants are randomly assigned to receive CoMPASS or usual care. The study plans to enroll 526 participants.

What's involved

Participants in the CoMPASS group will receive 9 contingency management sessions. If PrEP adherence isn't met by week 12, additional support services will be provided. The intervention lasts 24 weeks.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 12 months after the 24-week intervention period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.